School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China; State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100000, China.
School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China.
Drug Discov Today. 2022 Jul;27(7):1924-1935. doi: 10.1016/j.drudis.2021.10.019. Epub 2021 Oct 30.
Drug repurposing is an attractive strategy for identifying new indications for existing drugs. Three approved antidepressants have advanced into clinical trials for cancer therapy. In particular, further medicinal chemistry efforts with tranylcypromine (TCP) have led to the discovery of several TCP-based histone lysine specific demethylase 1 (LSD1) inhibitors that display therapeutic promise for treating cancer in the clinic. Thus repurposing antidepressants could be a promising strategy for cancer treatment. In this review, we illustrate the anticancer mechanisms of action of antidepressants and also discuss the challenges and future directions of repurposing antidepressants for anticancer drug discovery, to provide an overview of approved antidepressant cancer therapies.
药物重定位是一种有吸引力的策略，可用于确定现有药物的新适应症。三种已批准的抗抑郁药已进入癌症治疗的临床试验。特别是，曲安西龙（TCP）的进一步药物化学研究导致发现了几种基于 TCP 的组蛋白赖氨酸特异性去甲基酶 1（LSD1）抑制剂，它们在临床上显示出治疗癌症的治疗潜力。因此，重新利用抗抑郁药可能是癌症治疗的一种有前途的策略。在这篇综述中，我们说明了抗抑郁药的抗癌作用机制，并讨论了重新利用抗抑郁药进行抗癌药物发现的挑战和未来方向，为已批准的抗抑郁药癌症治疗提供了概述。
